e-learning
resources
Munich 2014
Sunday, 07.09.2014
ILDs 2
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts
B. Loeh, F. Drakopanagiotakis, G. P. Bandelli, E. Cordani, S. Tello, D. von der Beck, W. Seeger, P. Markart, A. Guenther, C. Albera (Giessen, Germany; Torino, Italy)
Source:
International Congress 2014 – ILDs 2
Session:
ILDs 2
Session type:
Thematic Poster Session
Number:
762
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Loeh, F. Drakopanagiotakis, G. P. Bandelli, E. Cordani, S. Tello, D. von der Beck, W. Seeger, P. Markart, A. Guenther, C. Albera (Giessen, Germany; Torino, Italy). Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts. Eur Respir J 2014; 44: Suppl. 58, 762
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort
Source: International Congress 2014 – ILDs 4
Year: 2014
Reduction in disease progression with nintedanib in the INPULSIS™ trials
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Sensitivity analyses from the INPULSIS™ trials of nintedanib
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 3
Year: 2014
Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014
Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS
Source: International Congress 2014 – ILDs 4
Year: 2014
Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP)
Source: International Congress 2014 – IPF and surroundings
Year: 2014
LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations
Source: International Congress 2014 – ILDs 6
Year: 2014
The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital
Source: International Congress 2014 – ILDs 4
Year: 2014
Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial
Source: International Congress 2014 – ILDs 3
Year: 2014
Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study
Source: International Congress 2014 – ILDs 6
Year: 2014
Comparison of physiological impairment in ILD patients with and without diagnostic IPF features
Source: International Congress 2014 – ILDs 4
Year: 2014
Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 2
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept